Visceral leishmaniasis infection during adalimumab therapy: a case report and literature review

Int J Rheum Dis. 2014 Sep;17(7):822-4. doi: 10.1111/1756-185X.12427. Epub 2014 Jul 1.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Review

MeSH terms

  • Adalimumab
  • Aged
  • Amphotericin B / therapeutic use
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antiprotozoal Agents / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Arthritis, Rheumatoid / diagnosis
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Bone Marrow Examination
  • Drug Substitution
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunocompromised Host
  • Leishmaniasis, Visceral / chemically induced*
  • Leishmaniasis, Visceral / diagnosis
  • Leishmaniasis, Visceral / drug therapy
  • Leishmaniasis, Visceral / immunology
  • Leishmaniasis, Visceral / parasitology
  • Male
  • Methylprednisolone / therapeutic use
  • Predictive Value of Tests
  • Risk Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antiprotozoal Agents
  • Antirheumatic Agents
  • Glucocorticoids
  • liposomal amphotericin B
  • Amphotericin B
  • Adalimumab
  • Methylprednisolone